Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Do docetaxel nanoparticles boost response in mCRPC?

Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Key clinical point: A docetaxel-encapsulating nanoparticle targeted against prostate-specific membrane antigen (PSMA) was safe and showed good activity in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) .

Major finding: The 6-month progression-free survival rate, the primary endpoint, was 65%.

Study details: Open-label, phase 2 trial of 42 men with mCRPC that progressed on abiraterone acetate and/or enzalutamide.

Disclosures: The study was funded by BIND Therapeutics and by grants from the National Institutes of Health, Sidney Kimmel Center for Prostate and Urologic Cancers, and the David H. Koch Prostate Cancer Research Fund. Dr. Autio had no disclosures. Several coauthors are employees of BIND Therapeutics, and others are employed by Epic Sciences, maker of the CTC assay used in the study. Other coauthors reported advising/consulting, research support, and speakers bureau activities for multiple companies.

Source: Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Read the article.

Citation:

Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf

Must Reads in Genitourinary Cancer

Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.

Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Access to care linked to better outcomes in black men with prostate cancer, Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.

Statins may affect prostate cancer microenvironment, Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.

Prostate cancer risks higher in smokers, Foerster B et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1071.